Scalper1 News
Specialty drugmaker Akorn’s Q4 earnings met estimates Monday, but its 2014 guidance and a new accounting problem halted the IBD 50 stock dead in its tracks. Akorn (AKRX) said profit totaled 14 cents a share, up a penny from the year-earlier quarter and identical to analyst consensus. Sales rose 19% to $85 million, a bit above analysts’ $83 million. For the full 2013, sales rose 24% to $318 million while net income climbed 6% to 55 cents a share. Scalper1 News
Scalper1 News